Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (<scp>CAPTIVATE</scp>)
Lin Chang(University of California, Los Angeles), Jan Tack(KU Leuven), Kye Gilder(VistaGen Therapeutics (United States)), Anthony Lembo(Cleveland Clinic), Fabio Cataldi(Pfizer (United States)), Guibao Gu(Arena Pharmaceuticals (United States)), David C. Kunkel(University of California San Diego), Sharon Skare(Arena Pharmaceuticals (United States)), Brooks D. Cash(Baylor University Medical Center), Donald Lipkis(Sharp Grossmont Hospital), Stewart A. Turner(Amgen (United States)), Brett A. English(Arena Pharmaceuticals (United States)), Beatriz Lindstrom(Arena Pharmaceuticals (United States))
Cited by 33
Related Papers
Bowel Disorders
|Gastroenterology|2016|2.8k
Functional Gastroduodenal Disorders
|Gastroenterology|2006|2.4k
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
|Gastroenterology|2020|2.1k
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
|BMJ|2008|1.2k
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
|New England Journal of Medicine|2004|1.1k